As the Washington PDAB reviews its drug review process, the EACH Coalition submitted comments to the board outlining concerns with drug reviews and outlining ways to improve the process and protect patients.
Concerns are expressed that cost reviews and upper payment limits (UPLs) can further complicate an already complex healthcare marketplace and result in worse outcomes for patients, and creating a unique pricing structure in Washington would create state-specific conditions for coverage.